Gastric Cancer | Tumor

CYNK-101 Gets FDA Fast Track Designation for HER2-Positive Gastric/GEJ Cancers

January 18th 2022

The FDA will speed up their review of CYNK-101 plus chemotherapy and immune checkpoint inhibitors for the treatment of advanced HER2-postivie gastric or gastroesophageal adenocarcinomas.

It Takes a ‘Huge Clinic Village’ to Create a Dream Cancer Care Team

December 30th 2021

From nurse navigators to surgeons, clinical social workers and more, a patient with cancer often has a village of team members helping them achieve a smooth and successful treatment experience.

‘Don’t Be Afraid to Ask for a Second Opinion,’ Cancer Expert Says

December 22nd 2021

Communication, self-advocacy and having someone in your corner are all critical tools to bring to a cancer care visit, says an expert from MedStar Georgetown University Hospital.

5 Cancer Clinical Trials You May Have Missed

December 18th 2021

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

BOLD-100 Trial Receives FDA Clearance for Treatment of Advanced GI Cancers

November 4th 2021

The Food and Drug Administration gave clearance to Bold Therapeutics for a phase 1b/2a trial examining treatments for advanced GI cancers.

Drug Combo May Prevent Chemo-Induced Nausea and Vomiting in Some Patients

August 31st 2021

Aprepitant, palonosetron and dexamethasone curbed chemotherapy-induced nausea and vomiting in certain women with gastrointestinal cancers who were receiving FOLFIRI or FOLFOX regimens.

FDA Approves Jemperli for Certain Advanced Solid Tumors

August 17th 2021

The indication for the PD-1 blocking antibody now includes adults with mismatch repair-deficient recurrent or advanced disease, adding to the previous indication of endometrial solid tumors.

Staying Aware of Gastric Cancer Risk Factors in Young Adults

August 13th 2021

On behalf of Hope for Stomach Cancer, Dr. Yanghee Woo speaks with CURE® about risk factors for gastric cancer and the alarming rise in cases in young adults.

Looking Forward: Patients With Genetic Mutations Are Empowered to Make Plans

August 6th 2021

Knowing they’ve inherited a genetic mutation for stomach or breast cancer gives patients the power to plan ahead.

FDA’s Approval of Keytruda-Based Regimen for Certain Stomach Cancer Subtypes ‘Really Exciting’ For Patients

July 23rd 2021

The FDA’s recent approval of Keytruda in combination with trastuzumab and chemotherapy in the first-line setting is an exciting change for a group of patients with certain subtypes of stomach cancer, according to an expert.

Treating Cancer as Patients Age

July 20th 2021

As patients aged 65 or older receive a diagnosis of cancer, their treatment course and priorities may differ from their younger counterparts.

New Potential Immunotherapy Treatment Options in Advanced Esophageal Squamous Cell Carcinoma

June 28th 2021

Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.

Opdivo Combined with Yervoy or Chemo Improves Survival in Unresectable and Advanced Esophageal Cancer

June 5th 2021

Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

FDA Approves Opdivo for Adjuvant Treatment of Esophageal and Gastroesophageal Junction Cancer

May 20th 2021

Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this occurred.

FDA Approves Keytruda for Use With Trastuzumab and Chemotherapy for Subtypes of Stomach Cancer

May 5th 2021

Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.

FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer

April 16th 2021

The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.

Opdivo with Chemotherapy Treatment Under Priority Review by FDA Shows Promise for Patients with Advanced Gastrointestinal Cancers

March 21st 2021

In clinical trials, Opdivo in combination with chemotherapy improved overall survival and progression-free survival compared to chemotherapy alone.

‘I Knew Something Was Wrong Before the Doctors Did’

February 10th 2021

Theresa Germano sat down with HEAL® to discuss her journey with cancer, how her daughter became her hero and how listening to her body benefited her in the end.

Bavencio Shows No Improvement of Overall Survival for Patients with Gastric Cancers

January 21st 2021

For patients with gastric/ gastroesophageal cancer, treatment with Bavencio after chemotherapy shows favorable safety, but no overall survival improvement.

FDA Grants Priority Review for Opdivo for Several Gastrointestinal Cancers

January 20th 2021

The priority review will focus on Opdivo with chemotherapy for the treatment several gastrointestinal cancers, which has recently become a rising area in novel treatment development.

Alleviating Pandemic-Related Anxiety Over Returning to the Clinic for Clinical Trials

January 16th 2021

In an interview with CURE®, expert Martha Raymond explains the importance of clinical trials during the COVID-19 pandemic and how clinicians must find a way to help ease patients anxieties as they return to the clinic.

Enhertu Receives FDA Approval for Gastroesophageal, Gastric Cancer Subset

January 15th 2021

The Food and Drug Administration approved Enhertu to treat adults with locally advanced or metastatic HER2-positive gastroesophageal or gastric cancer who have previously received a trastuzumab-based treatment regimen.

Keytruda-Chemo Combo Granted Priority Review By FDA for Treatment of Advanced Esophageal, Gastroesophageal Junction Cancer

December 22nd 2020

The FDA granted a priority review to the supplemental biologics license application for the combination of Keytruda and chemotherapy for the firstline treatment of locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

How Superwoman Battled Stomach Cancer at Age 78

November 11th 2020

I am a nurse practitioner and a professor. But my best job was being a daughter and caregiver to the most wonderful mother anyone could ever have.

Announcing Hope Series Webinar From Hope For Stomach Cancer

October 15th 2020

Join us for our Inaugural 1st Hope Webcast on surgical strategies for Stage IV stomach cancer.

The Mind of Cancer

September 17th 2020

Cancer makes your mind wander in many strange directions. If ever you wanted to know what an emotional rollercoaster really felt like, get on the cancer coaster and go for a ride.

Debbie's Dream Foundation Announces the Gastroesophageal Cancer Educational Virtual Symposium in Partnership with Massachusetts General Hospital Cancer Center

September 8th 2020

Patients, caregivers, and families to gain virtual access to the latest topics in gastric cancer research from oncology experts.

Stomach Cancer Awareness

August 11th 2020

Hope for Stomach Cancer helps provide awareness for patients with stomach cancer and their caregivers.

Jennifer Higgins - A Survivor's Story

July 24th 2020

Surviving Hereditary Stomach Cancer Involves an Effort by the Whole Family

February 14th 2020

In an effort to combat hereditary stomach cancer, it takes the entire family to help understand what it takes.